The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Riastap 1 g Powder for Solution for Injection / Infusion



CSL Behring GmbHPA0800/007/001

Main Information

Trade NameRiastap 1 g Powder for Solution for Injection / Infusion
Active SubstancesHuman fibrinogen
Dosage FormPowder for solution for injection/infusion
Licence HolderCSL Behring GmbH
Licence NumberPA0800/007/001

Group Information

ATC CodeB02BB Fibrinogen
B02BB01 fibrinogen, human

Status

License statusAuthorised
Licence Issued24/09/2010
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Summary of Product Characteristics, section 4.2).
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back